As of 2025-09-18, the EV/EBITDA ratio of Alpine Immune Sciences Inc (ALPN) is -87.88. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ALPN's latest enterprise value is 4,423.93 mil USD. ALPN's TTM EBITDA according to its financial statements is -50.34 mil USD. Dividing these 2 quantities gives us the above ALPN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 15.9x | 14.8x |
| Forward P/E multiples | 17.8x - 19.2x | 18.5x |
| Fair Price | (12.58) - (11.19) | (11.72) |
| Upside | -119.4% - -117.2% | -118.0% |
| Date | EV/EBITDA |